Bruker Daltonics Introduces Novel WARP-LC™ 1.1 Software for LC/MS/MS Based Quantitative Proteomics; WARP-LC 1.1 Provides Comprehensive Support for All Current Label Chemistries Including ICPL, iTRAQ and ICAT

Business Wire, May 28, 2006

SEATTLE -- At the 2006 ASMS conference, Bruker Daltonics today announces its novel WARP-LC 1.1 software suite for quantitative proteomics using isotope labeling. WARP-LC is the first comprehensive solution for quantitative LC-MS/MS protein analysis.

All current industry-standard label chemistries are fully supported (ICPL, SILAC, iTRAQ, ICAT, and (18)O/(16)O-C-terminus labeling) and WARP-LC is open to other customized labelling technologies. Full support for multiplexed quantification (e.g., ICPL triplex, iTRAQ or SILAC 4plex) is provided, irrespective whether isobaric or non-isobaric labels are used. Median-based statistics provide highest data quality with automatic outlier detection and validation of quantitative results. WARP-LC has already demonstrated its outstanding performance using the ICPL chemistry during the Association for Biomolecular Research Facilities (ABRF)-PRG 2006 quantification study earlier this year.

WARP-LC is the single proteomics quantification platform for all Bruker Daltonics mass spectrometers: Flex-series MALDI TOF/TOFs, HCT-series ion traps, micrOTOF-Q and APEX-Q FTMS series. In addition, WARP-LC enables advanced data LC/MS visualization with SurveyViewer and ProteinBrowser functionality and extensive data validation and reporting tools.

WARP-LC also controls LC-MALDI data acquisition on Flex TOF/TOF systems, and enables result-dependent data acquisition when combining multiple LC-runs even across different instrument platforms (LC/ESI-MALDI). WARP-LC directly interact with Bruker Daltonics' BioTools 3.0 software for advanced protein sequence validation, PTM screening, de novo sequencing and MS-BLAST searches for full protein structure elucidation. In addition, a link to Bruker Daltonics' ProteinScape 1.3 puts individual LC/MS/MS analyses onto the proteomics project level.

In particular, WARP-LC fully supports the new ICPL Triplex labeling kit introduced by SERVA Electrophoresis and Bruker Daltonics at this ASMS conference, which permits the simultaneous analysis of three different proteomic states. ICPL has been developed to be used in gel based workflows, as well as for LC/MS/MS workflows.

Dr. Arnd Ingendoh, Assistant Vice President for Proteomics at Bruker Daltonics, said: "WARP-LC 1.1 provides unique flexibility to the protein researcher. This single software platform supports labeling experiments on the proteomics scale independent of the choice of labeling chemistry or MS technology platform. WARP-LC 1.1 is fully consistent with the growing requirement for protein pre-fractionation to obtain deeper insights into the proteome composition."

ASMS 2006, the 54th American Society for Mass Spectrometry Conference will be held May 28 - June 1, 2006 in Seattle, Washington in the Washington State Convention & Trade Center.

ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR)

Bruker BioSciences Corporation, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc. and Bruker AXS Inc. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. Bruker Daltonics also offers a broad line of nuclear, biological and chemical (NBC) detection products for defense and homeland security. Bruker AXS is a leading developer and provider of life science, materials research and industrial X-ray analysis tools. For more information about Bruker BioSciences Corporation, please visit www.bruker-biosciences.com

CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the companies' reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the companies' products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K, our most recent quarterly reports on Form 10-Q, and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements.

Trademarks:
ICPL is a trademark of Toplab GmbH
iTRAQ is a trademark of Applera Corporation
ICAT is a trademark of the University of Washington